Invitation to presentation in connection with EQL Pharma's quarterly report, first quarter, 2023/24
EQL Pharma AB (publ) will publish its quarterly report for the first quarter, 2023/24, on Wednesday, August 16th, after stock markets closening.
At 10.00 (CET) 17th August, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate.
Use the following link to access the virtual meeting: https://tinyurl.com/4cfkfwen
Date and time
August 17th, 2023, at 10.00 (CET) the presentation starts. Time required for presentation and subsequent question time is estimated at a maximum 1 hour.
Make sure you are able to attend the video conference by logging in shortly before the start of the conference.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.